Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 14/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23144761 | 0.81 | MAPK7 (0.53) | TNK2MAPK7LRRK2DCLK1 | |
| SCHEMBL10098791 | 0.80 | TNK2 (0.56) | TNK2MAPK7LRRK2 | |
| SCHEMBL16065715 | 0.72 | TNK2 (0.40) | TNK2RAB9ACHRM2 | |
| SCHEMBL12426018 | 0.70 | JUN (0.31) | — | |
| SCHEMBL14330946 | 0.68 | JUN (0.32) | — | |
| SCHEMBL8302193 | 0.68 | RAB9A (0.46) | RAB9ACHRM2 | |
| SCHEMBL8303072 | 0.68 | RAB9A (0.46) | RAB9ACHRM2 | |
| SCHEMBL14330942 | 0.68 | JUN (0.32) | — | |
| SCHEMBL20462815 | 0.66 | TDP1 (0.50) | — | |
| SCHEMBL19436609 | 0.65 | TNK2 (0.51) | TNK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4034132-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061894-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | TNK2 1688/4885RAB9A 1982/4885MAPK7 30/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | TNK2 933/4885RAB9A 1280/4885MAPK7 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.